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Background and purpose: The regulatory guidelines (ICHS7B) recommending inhibition of the delayed rectifier K
þ current
(IKr), carried by human ether-a-go-go-related gene (hERG) channels in cardiac cells (the hERG test), as a ‘first line’ test for
identifying compounds inducing QT prolongation, have limitations, some of which are outlined here.
Experimental approach: hERG current was measured in HEK293 cells, stably transfected with hERG channels; action potential
duration (APD) and arrhythmogenic effects were measured in isolated Purkinje fibres and perfused hearts from rabbits.
Key results: 576 compounds were screened in the hERG test: 58% were identified as hERG inhibitors, 39% had no effect and
3% were classified as stimulators. Of the hERG inhibitors, 92 were tested in the APD assay: 55.4% of these prolonged APD,
28.3% had no effect and 16.3% shortened APD. Of the 70 compounds without effect on hERG channels, 54.3% did not affect
APD, 25.7% prolonged, while 20% significantly shortened APD. Dofetilide (hERG inhibitor; IC50,2 9n M) prolonged QT and
elicited early after-depolarizations and/or torsade de pointes (TdP) in isolated hearts. Mallotoxin and NS1643 (hERG current
stimulators at 3mM), levcromakalim and nicorandil (no effect on hERG current), all significantly shortened APD and QT, and
elicited ventricular fibrillation (VF) in isolated hearts.
Conclusion and implications: The hERG assay alone did not adequately identify drugs inducing QT prolongation. It is also
important to detect drug-induced QT shortening, as this effect is associated with a potential risk for ventricular tachycardia and
VF, the latter being invariably fatal, whereas TdP has an B15–25% incidence of death.
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Introduction
In the heart, drug-induced prolongation of the QT interval
and the appearance of torsade de pointes (TdPs) are
recognized as potential risks associated with the use of a
broad range of cardiovascular and non-cardiovascular drugs
(Haverkamp et al., 2000; Cubeddu, 2003; Shah, 2004).
Current established regulatory guidelines (CPMP/986/96,
1997 and International Conference on Harmonisation
(ICH) S7B, 2005) recommend the use of preclinical studies
to detect drug-induced QT interval prolongation and
arrhythmogenic potential.
The most common mechanism for drugs that induce
prolongation of the QT interval is the inhibition of the
rapidly activating delayed rectifier potassium current (IKr)o f
the cardiac cells. IKr is the key current responsible for phase 3
repolarization of the cardiac action potential and is con-
veyed by the human ether-a-go-go-related gene-encoded,
voltage-dependent potassium channel (hERG channel). As
such, the current regulatory guidelines recommend the
hERG test for identifying drugs with potential QT liabilities.
BJPOpen   
Received 12 February 2008; revised 1 April 2008; accepted 10 April 2008;
published online 19 May 2008
Correspondence: Dr HR Lu, Center of Excellence for Cardiovascular Safety
Research, Johnson & Johnson Pharmaceutical Research & Development,
Division of Janssen Pharmaceutica NV, Beerse, Antwerp B-2340, Belgium.
E-mail: hlu@prdbe.jnj.com
British Journal of Pharmacology (2008) 154, 1427–1438
& 2008 Nature Publishing Group All rights reserved 0007–1188/08 $30.00
www.brjpharmacol.orgDrug-induced long QT and its risk for TdPs are now well
known because, in recent years, extensive progress has been
made in studying the congenital long QT syndromes (Roden,
2008), and also in drug-induced TdP through different
screening strategies, evaluated following the release of
CPMP/986/96 in 1997. Conversely, little is known about
genetic short QT syndromes, characterized by abnormally
short QT intervals (o300ms), atrial fibrillation, palpitations,
syncope and sudden death due to ventricular fibrillation (VF)
(Gaita et al., 2003; Giustetto et al., 2006). As it is difficult to
capture QT shortening in the setting of the associated fatal
arrhythmia (VF), knowledge concerning drug-induced short
QT intervals is sparse, with only a few publications,
suggesting that a short QT interval could potentially increase
the risk of sudden death (D’Alonzo et al., 1994, 1998;
Extramiana and Antzelevitch, 2004; Hondeghem, 2006;
Garberoglio et al., 2007). Indeed, the present ICH S7B
guideline (Food & Drug Administration, 2005) does not
specifically address the possibility of a drug-induced short-
ening of the QT interval and its potential for development of
fatal arrhythmias.
Our present study was carried out on over 500 bioactive
compounds from Johnson & Johnson’s current research
programmes, and also included 5 reference compounds—
dofetilide, mallotoxin, NS1643, levcromakalim and nicor-
andil—with known mechanisms of action. Our findings
showed that an appreciable number of compounds did not
affect the hERG channel, but did prolong the action
potential duration (APD). Additionally, although many
compounds did prolong APD and QT, a relatively large
number of compounds shortened APD and QT, and several
of these could precipitate ventricular tachycardia (VT) and
VF. These observations identify a serious gap in the design of
the present guidelines to identify and eliminate potentially
arrhythmogenic compounds. Some of the data in this paper
have been published in abstract form (Lu et al., 2008).
Materials and methods
All experimental procedures were performed in accordance
with the provisions of the European Convention on the
protection of vertebrate animals, which are used for experi-
mental and other scientific purposes, and with ‘the Appen-
dices A and B’, made at Strasbourg on March 18, 1986
(Belgian Act of October 18, 1991).
Effects of drugs on hERG current
The experimental approach we used is similar to that
employed in other studies (Volberg et al., 2002; Dubin
et al., 2005; Lu et al., 2007). A human embryonic kidney cell
line (HEK293) with a stable transfection of hERG was used
(purchased from Dr Z Zhou, University of Wisconsin,
Madison, WI, USA). The cells were cultured in MEM
(Minimum Essential Medium, GIBCO, Invitrogen Corporation;
Carlsbad, USA) supplemented with (amounts added to
500ml MEM): 5ml L-glutamine–penicillin–streptomycin
(Sigma, St Louis, MO, USA), 50ml foetal bovine serum
(Bio-Whittaker, Walkersville, USA), 5ml non-essential amino
acids 100  (GIBCO), 5ml sodium pyruvate 100mM
(GIBCO) and 4ml geneticin 50mgml
 1 (GIBCO) at 371C
in 5% CO2 atmosphere. Before use, the cells were seeded in
small Petri dishes precoated with poly-L-lysine (Biocoat,
Becton Dickinson Labware; Bedford, USA). Experiments were
carried out 1 2 days after plating.
Conventional patch-clamp experiments. Recordings were con-
ducted at room temperature. Solutions used were as follows:
the bath solution contained (in mM) 150 NaCl, 4 KCl,
1 MgCl2, 1.8 CaCl2, 10 HEPES, 5 glucose (pH 7.4 with
NaOH). The pipette solution contained (in mM) 120KCl, 10
HEPES, 5 EGTA, 4 ATP-Mg2, 2 MgCl2, 0.5 CaCl2 (pH 7.2 with
KOH). Solutions were applied to the cell under study using a
Y-tube system, allowing a rapid delivery and mixing of
solutions in the vicinity of the cell under study. The
membrane current of the cells was measured at distinct
membrane potentials by means of an EPC-9 patch clamp
amplifier (HEKA, Lambrecht/Pfalz, Germany). Data were
acquired and analysed using the programs Pulse and
PatchmasterPro (HEKA, HEKA Elektronik, GmbH; Lambrecht
/Pfalz, Germany), Data Access (Bruxton, Seattle, USA), Igor
(Wavemetrics, Lake Oswego, USA) and Excel (Microsoft,
Redmond, USA). After disruption of the membrane, the cell
capacitance and the series resistance were compensated (90%)
using the circuit of the EPC-9 patch clamp amplifier. The
holding potential was –80mV. The hERG-mediated current
(K
þ-selective outward current) was determined as the
maximal tail current at  40mV after a 2s depolarization to
þ60mV. Pulse cycling rate was 15 s. Before each test pulse, a
short pulse (0.5s) to  60mV was given to determine leak
current. The protocol consisted of a 5min equilibration
period (no pulses), 5min in control solution and then 5min
for each concentration of the drug. Up to three concentra-
tions were tested per cell (0.001–100mM). Rundown of the
hERG current was taken into account by extrapolating the
gradual decrease in current measured during the 5min in
control solution to the remaining duration of the experi-
ment. The effect of the drug was measured after 5min of
drug application by dividing the measured current by the
extrapolated current.
In addition to the conventional patch clamp, for some
compounds, the hERG test was performed by an automated
patch clamp system (PatchXpress 7000A). This experimental
approach was similar to that described earlier (Dubin et al.,
2005).
Effects of drugs in isolated rabbit Purkinje fibres
Electrophysiological experiments were performed on iso-
lated Purkinje fibres from female rabbits, using conventional
microelectrode techniques. The approach is similar to that
used in recent studies from our laboratories (Lu et al., 2001).
Briefly, Purkinje fibres were isolated from left ventricles
within 5min after the death of the animal and stored in a
tissue bath. The cardiac tissues were perfused with gassed
(95% O2 and 5% CO2) Tyrode’s solution of the following
composition (in mM): NaCl 136.9, KCl 4, CaCl2 1.8, MgCl2
1.04, NaHCO3 11.9, NaH2PO4 0.42 and glucose 5.5. The
preparations were fixed at the bottom of a 2.5-ml perfusion
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superfused with oxygenated Tyrode’s solution at a rate of
2.7mlmin
 1 together with solutions of the reference
compounds or solvent at a rate of 300mlmin
 1. The
temperature in the bath was kept at 35.5±1.01C.
The Purkinje fibres were stimulated at a basal rate of 1Hz
(60 beats per minute or 1000ms cycle length) through
bipolar Teflon-coated silver wire electrodes that were con-
nected to a pulse generator and an isolation transformer.
Stimuli consisted of regular pulses of 0.5–1ms duration,
delivered at an intensity of two times the diastolic threshold.
Intracellular potentials were recorded with glass microelec-
trodes filled with 2.7M KCl, with tip resistances between 5
and 65MO. The microelectrode was connected to the
headstage of the microelectrode amplifier (Hugo Sachs
Elektronik: HSE; type 695; March-Hugstetten, Germany).
Action potential signals were acquired by action potential
software (Notocord-Hem 3.5, Paris) at a sampling rate of
20kHz, filtered at 100Hz. The signals were stored on a
personal computer for subsequent analysis. The optimal
stimulation site of the preparation was determined as the site
where a normal and stable action potential could be
induced. The maximum rate of rise of the action potential
was obtained by electronic differentiation (Vmax in Vs
 1).
The amplitude of action potential (AAP in mV), and APD at
40, 50 or 90% repolarization (APD40, APD50 or APD90 in ms)
were determined from the recordings.
Control values (baseline values before contact with solvent
or compound) were determined after a stabilization period,
when the measured variables had reached a steady state. The
electrophysiological parameters were again measured during
the experimental period.
After baseline values had been recorded at 1Hz, solvent or
one of the testing compounds at four concentrations (0.01–
10mM or 0.1–100mM)( n¼5–7 for each compound) was
continuously superfused for 15min for each concentration
at a stimulation rate of 1Hz. In addition, the stimulation rate
was reduced to 0.2Hz at the highest concentration for
another 5min, because preparations are more prone to
induction of early after depolarizations in a condition of
extreme bradycardia (Lu et al., 2001).
Effects of drugs in isolated Langendorff-perfused rabbit hearts
The method for determining various cardiac electrophysio-
logical properties was similar to, and has been described in
detail as, the isolated, Langendorff-perfused rabbit heart
(Hondeghem et al., 2003; Lu et al., 2007). Briefly, Langendorff
experiments were performed on the hearts isolated from
about 2.5kg female albino rabbits. The heart was perfused at a
constant pressure of 80cm H2O with a bicarbonate buffer (in
mM: NaCl 118, KCl 3.5, NaHCO3 22, MgCl2 1.1, NaH2PO4 0.4,
CaCl2 1.8, glucose 5, pyruvate 2 and creatine 0.038, gassed
with 95% O2 and 5% CO2, pH adjusted to 7.4, at 371C). Under
a dissection microscope, the bundle of His was cut and a
stimulating electrode sutured on each side of the distal His
bundle. A recording electrode was advanced until it reached
the left ventricular endocardium of the septum.
Stimulation current was adjusted, and automaticity, escape
cycle lengths, conduction times and APDs for cycle lengths
at 2000, 1500, 1000, 750, 500, 300 and 250ms were
determined. Trains of 5s at cycle lengths of 250, 500, 750
and 1000ms were recorded. APD90 or APD60, triangulation
(APD90–APD30), short-term beat-to-beat instability of the
APD90 (Lu et al., 2007), conduction time and coronary flow
were measured during experimental periods. A bath ECG
from the Lead II, reflecting the propagation of action
potential waves Q, R, S, J and T, was placed and recorded.
ECG parameters such as QRS duration, QT interval, JT
interval, transmural dispersion (Tp-Te) [¼QTpeak-QTend],
rTp-Te (Tp-Te/QT-interval 100) (Shimizu and Antzelevitch,
1997; Yan et al., 2001; Extramiana and Antzelevitch, 2004)
were also measured. Conduction time was measured as the
interval between the electrical stimulation to the point
where the action potential just started the depolarization
(upstroke of the action potential).
The solvent or drug solutions (four concentrations of the
testing compound from 0.001 to 100mM; n¼6–8 for each
compound) were perfused for 30min per concentration.
Monophasic action potentials from the inside of the left
ventricle, the right and left epicardium and ECG were
recorded and digitized at 1kHz (12 bits). For the conduction
data, sampling was done at 10kHz (each channel). Data were
analysed beat by beat during the experiment, and the results
were compressed and saved to disc.
Data analysis
All values are expressed as mean and s.e.mean. Statistically
significant differences between solvent and compound were
calculated based on their changes from baseline with the
Mann–Whitney U-test. For the evaluation of differences in
the incidence of VF, Fisher’s exact test was used. Two-tailed
probabilities of less than 0.05 were considered to indicate
statistically significant differences.
Materials
A total of 635 novel compounds from Johnson & Johnson’s
worldwide research projects were used. Reference
compounds such as levcromakalim, nicorandil and mallo-
toxin were obtained from Sigma (St Louis, MO, USA), and
NS1643 was gratefully received from Dr M Grunnet (Neuro-
Search A/S, Ballerup, Denmark). The compounds were
dissolved in pyrogen-free water (acidified with tartaric acid
to obtain a pH of approximately 4), buffer solution or in
dimethyl sulphoxide (final bath concentration of 0.1 or
0.3%). Similar solutions without compound were used as
solvent controls.
Results
Criteria for the assessment of effects of compounds on hERG
current and on APD in vitro
The effect of each compound, on the variables measured,
was expressed as the solvent-corrected net effect. An
effect was defined as ‘hERG inhibition’ if a compound
inhibited hERG current by X20% at a concentration p3mM,
as ‘hERG stimulation’ (or activation of hERG) if a compound
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or was considered as ‘no effect’ if a compound was
associated with o20% inhibition or o10% activation of
hERG current at a concentration p3mM (n¼3–5 per
compound and per concentration) or effects appeared only
at high concentrations (43mM). An effect was defined as a
prolongation of the APD if the compound induced X10%
prolongation of APD at 90% repolarization (APD90)i n
isolated Purkinje fibres or of APD at 60% repolarization
(APD60) in isolated, Langendorff-perfused hearts, at any
tested concentration (n¼6–8). An effect was defined as a
shortening of APD if the compound induced X10% short-
ening of APD90 or APD60 at any tested concentrations. The
compound was considered as having no effect if it induced a
change in APD90 or APD60 between  10% and þ10% change
from the baseline value.
Effects on hERG
A total of 576 compounds were tested in the hERG test. Of
these, 58% (n¼333) inhibited hERG current, 39% (n¼226)
had no effect on the hERG current and 3% (n¼17) were
found to stimulate hERG current (upper part of Figure 1).
Effects on APD
A total of 229 compounds were screened in the action
potential tests (isolated Purkinje fibres or isolated Langen-
dorff-perfused hearts). Of these, 44% (n¼100) were found to
prolong the duration of the action potential, 39% of these
229 compounds (n¼89) had no effect on APD, whereas 17%
(n¼40) were found to significantly shorten APD (lower part
of Figure 1).
Effects on hERG and APD
A total of 170 compounds were tested in both the hERG
assay and an action potential assay (isolated Purkinje fibres
or isolated Langendorff-perfused hearts). Of these 170
compounds, 54% (n¼92) were found to block hERG current,
41% (n¼70) were without effect and 5% (n¼8) were found
to activate hERG current.
Of the 92 compounds inhibiting hERG current, 55.4%
(n¼51) prolonged APD, 16.3% (n¼15) shortened APD and
28.3% (n¼26) did not change APD (upper part of Figure 2).
Of the 70 compounds without effect in the hERG test, 54.3%
(n¼38) did not change APD, 20% (n¼14) shortened APD,
but surprisingly 25.7% (n¼18) still prolonged APD (middle
part of Figure 2).
Of the eight compounds found to be hERG stimulators or
‘activators’, three had no effect on APD, two prolonged APD,
whereas three compounds, including NS1643 and mallotoxin,
shortened APD (lower part of Figure 2).
Effects of reference compounds on hERG
Levcromakalim had no effect on hERG current up to a
concentration of 10mM, and nicorandil did not affect hERG
current up to a concentration of 100mM. As expected,
mallotoxin activated hERG current by 87% at 3mM, and
NS1643 activated hERG current by 55% at 3mM. Dofetilide
blocked hERG current with an IC50 of 29nM. Figure 3 shows
an example of the effects of dofetilide and NS1643 in the
hERG assay.
Effects of five reference compounds on the action potential: in
isolated Purkinje fibres or in isolated Langendorff-perfused hearts
Dofetilide (n¼7), which inhibited hERG current with an
IC50 of 29nM, concentration-dependently prolonged APD in
isolated Purkinje fibres, increased triangulation of the action
potential and elicited early after-depolarizations starting at a
concentration of 0.01mM. (example on the right side of
3%
44%
17%
HERG Test
(n = 576)
39%
58%
inhibition no effect stimulation
APD Test
(n = 229)
39%
prolongation no effect shortening
Figure 1 Upper part: effects of 576 compounds on the hERG
current. Inhibition: X20% inhibition of hERG current at a concen-
tration p3mM; no effect: o20% inhibition or o10% activation of
hERG current at a concentration p3mM or effects appeared only at
high concentrations (43mM); hERG stimulation (activation): X10%
activation of hERG at a concentration p3mM (n¼3–5 per
concentration). Lower part: effects of 229 compounds on the
duration of the action potential at 60 or 90% repolarization (APD60
or APD90) on isolated rabbit Purkinje fibres or on isolated
Langendorff-perfused rabbit hearts. ‘Prolongation’ was defined as a
prolongation of the action potential duration (APD) if the compound
induced X10% prolongation of APD at 90% repolarization (APD90)
in isolated rabbit Purkinje fibres or of APD at 60% repolarization
(APD60) in isolated, Langendorff-perfused rabbit hearts, at any tested
concentration (n¼6–8). ‘Shortening’ was defined as a shortening of
APD if the compound induced X10% shortening of APD90 or APD60 at
any tested concentrations. ‘No effect’ was defined as an effect between
 10% and þ10% change from baseline in APD90 or APD60.
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dofetilide (n¼7) significantly prolonged the APD90 starting
at 0.001mM and QT interval starting at 0.01mM, and tended
to increase Tp-Te starting at a concentration of 0.01mM.
The compound significantly increased the triangulation
of the action potential at 0.01mM and the beat-to-beat
instability at 0.1mM and elicited early after-depolarizations
and TdP starting at 0.01mM (example on the left side of
Figure 4).
The other reference compounds (mallotoxin, NS1643,
levcromakalim and nicorandil) are all known to shorten
APD and QT interval and were only studied in the isolated
heart. Mallotoxin, which activated hERG current by 87%
at 3mM in hERG-transfected HEK293 cells, significantly
shortened the QT interval, JT interval and APD and increased
Tp-Te and rTp-Te and coronary flow at 0.1mM.A t1 mM,
mallotoxin elicited VT in 2 out of the 7 hearts and VF in 7
out of the 7 hearts (versus 0 out of the 12 hearts with
solvent). These effects are illustrated by the experimental
results shown in Figure 5.
NS1643, which activated hERG current by 55% at 3mM in
hERG-transfected HEK293 cells, significantly shortened APD
and increased coronary flow at 1 and 10mM.A t1 0 mM, the
compound shortened the QT and JT interval and tended to
increase the Tp-Te. Furthermore, NS1643 elicited VT in one
out of the six hearts at 1mM and VF in four out of the six
hearts at 10mM.
Levcromakalim, which did not affect hERG current at the
concentrations tested, was also studied in detail in the
shortening prolongation no effect
25.0%
37.5%
37.5%
HERG stimulators vs APD (n = 8)
20.0% 25.7%
HERG no effect vs APD (n = 70)
HERG inhibitors vs APD (n = 92)
54.3%
55.4%
16.3%
28.3%
Figure 2 Effects of a selection of compounds with known effects in
the hERG test, on APD (isolated Purkinje fibres or isolated
Langendorff-perfused hearts). Upper part: hERG inhibitors. Middle
part: compounds without effect on hERG. Lower part: hERG
stimulators.
-80 mV
-60 mV
+60 mV
-40 mV
2 s
200 pA
control
+ 0.01 µM dofetilide
+ 0.03 µM dofetilide
+ 0. 3 µM dofetilide
2 s
200 pA
control
+ 1 µM NS1643 
+ 3 µM NS1643 
+ 10 µM NS1643 
Figure 3 Effect of dofetilide and NS1643 on the membrane K
þ
current (IKr) in hERG-transfected HEK293 cells. Upper part: schematic
representation of the pulse protocol: a small test pulse to  60mV to
determine the leak current, a depolarizing pulse to þ60mV to
activate the K
þ current, and a pulse to  40mV to deactivate the K
þ
current and elicit the large tail current (which is used to determine
the amplitude of the K
þ current IKr). Finally, the cells are clamped
back to the holding potential of  80mV. This protocol is repeated
every 15s. Lower part: superimposed current traces in one cell in
different conditions: solvent control solution and increasing con-
centrations of dofetilide or NS1643. Dofetilide inhibited hERG
current with an IC50 of 29nM and NS1643 activated hERG current
by 55% at 3mM.
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tened QT interval and APD and increased coronary flow at
0.1mM and increased rTp-Te at 1.0mM.A t1 0 mM, levcroma-
kalim markedly changed these parameters. Furthermore, the
compound elicited VT in three out of eight hearts at 1mM,
and VF in seven out of eight hearts at 10mM. Figure 6 shows
the shortening of the QTand JT intervals and of APD and the
induction of VT in an isolated Langendorff-perfused heart in
the presence of 1mM levcromakalim.
Nicorandil, like levcromakalim, did not affect hERG
current. However, nicorandil slightly shortened the QT and
JT intervals and APD, increased coronary flow, Tp-Te and
MAP 3 EAD
500 ms
10 mV
MAP 2
MAP 1
ECG
Isolated heart
TdP
Purkinje fiber
1Hz (baseline)
1Hz (20 min)
0.2Hz (23 min)
0
-90
0
-90
0
-90
EADs
800 ms
25 mv
Figure 4 The effect of dofetilide on action potential morphology in an isolated Purkinje fibre (right side of the figure) and on ECG and MAP
recordings in the isolated heart. The compound prolonged the duration of the action potential (APD) and elicited early after-depolarizations
(EADs) at a stimulation rate of 0.2Hz at 0.01mM in the Purkinje fibre, and prolonged the QT interval/APD and elicited EAD and TdP at 0.01mM
in an isolated Langendorff-perfused heart. ECG: electrocardiogram recording. MAP1, the left ventricular epicardial monophasic action potential
(MAP) recording; MAP2, right ventricular MAP recording; MAP3, left intra-ventricular MAP recording.
VF VF
500 ms
10 mV
MAP 3
MAP 2
MAP 1
ECG
Baseline
Figure 5 The effect of mallotoxin on ECG and MAP recordings in the isolated heart. At 1mM, mallotoxin shortened QT and the duration of the
action potential and elicited ventricular fibrillation (VF). ECG, electrocardiogram recording; MAP1, the left ventricular epicardial monophasic
action potential (MAP) recording; MAP2, right ventricular MAP recording; MAP3, left intra-ventricular MAP recording. T wave was inverted and
narrowly peaked.
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only two out of the six hearts at a higher concentration of
100mM.
The effects of the four compounds on the incidence of VF,
APD, the duration of the QT and JT intervals, Tp-Te, rTp-Te
and beat-to-beat instability before VF are summarized in
Figures 7–10. The incidence of VF by the compounds was
associated with shortening in the ventricular repolarization
(QT-interval, JT-interval and APD90) and increases in the
transmural dispersion (Tp-Te and rTp-Te), just before the VF.
These four compounds, however, did not significantly
change ventricular conduction time or triangulation of the
action potential (data not shown).
Discussion and conclusions
The hERG (IKr)-testing paradigms recommended in the
present regulatory guidelines (ICH S7B, 2005) for
predicting drug-induced QT prolongation may not
adequately describe all the conditions needed to efficiently
eliminate those compounds able to induce QT
prolongation and hence TdP. Even more concerning is the
fact that the ICH guidelines fail to address the possibility
of precipitation of other, potentially more life threatening,
drug-induced cardiac arrhythmias such as VT and
VF, associated with drug-induced shortening of the QT
interval.
VT
500 ms
10 mV
MAP 3
MAP 2
MAP 1
Baseline
ECG
Figure 6 The effect of levcromakalim on ECG and MAP recordings in the isolated heart. Levcromakalim shortened APD and elicited ventricular
tachycardia (VT) at 1mM. ECG, electrocardiogram recording; MAP1, the left ventricular epicardial monophasic action potential (MAP)
recording; MAP2, right ventricular MAP recording; MAP3, left intra-ventricular MAP recording.
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Solvent Mallotoxin Levcromakalim Nicorandil NS1643
Incidence of VF (%)
Changes in APD90 (%)
Figure 7 Drug-induced effects on APD90 (values were taken just before the induction of VF and expressed as % changes from baseline) and
incidence of ventricular fibrillation (VF) (in %) in isolated, Langendorff-perfused hearts. Data of mallotoxin (n¼7) were obtained at 1mM,
NS1643 (n¼4) and levcromakalim (n¼7) were obtained at 10mM and nicorandil (n¼2) was obtained at 100mM. APD90: the duration of the
action potential at 90% repolarization. Values were taken from the hearts with VF. *Po0.05 versus solvent.
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interactions with the hERG ion channel and numerous
papers confirm that inhibition of hERG (IKr) is a common
feature of many drugs capable of inducing TdP in man
(Haverkamp et al., 2000; Cubeddu, 2003; Shah, 2004).
Therefore, the blockade of hERG current remains the
predominant risk factor in drug-induced TdP. Figure 3 shows
that dofetilide inhibited hERG current with an IC50 of
29nm, markedly prolonged APD in isolated Purkinje fibres
and largely prolonged APD and QT and elicited TdP in
isolated hearts (Figure 4). In the clinic, the concept of drug-
induced TdP, resulting from hERG channel inhibition, is
supported by the congenital long QT syndrome (LQT2)
which is manifested by mutations of the hERG gene (Chiang
and Roden, 2000). However, despite possessing such a
mutation, not all patients with a variant hERG channel
present with a clear long QT interval. Furthermore, muta-
tions in other genes for cardiac ion channels such as IKs (the
slowly activating delayed rectifier potassium current) or
SCN5A (encodes for the cardiac voltage-gated Na
þ channel)
can also lead to long QT in man, which sometimes results in
TdPs. Thus, unravelling the mechanisms underlying con-
genital long QT syndromes suggests that factors other than
hERG channel inhibition and QT prolongation may also be
involved in drug-induced TdP. Therefore, although the hERG
test to predict drug-induced long QT is very useful, this test
alone may not be able to ascertain fully the potential for
precipitation of TdP.
In our present study we have shown that (1) not all drugs
that block the hERG ion channel prolong QT and APD, and
that (2) some drugs that do not inhibit the hERG channel are
not necessarily free of the risk of drug-induced long QT and
TdP (Figure 2). Compounds that potently block the hERG
current, but normally do not prolong QT and APD, include
Ca
2þ blockers (such as verapamil) and some Na
þ channel
blockers. Thus, flecainide inhibits hERG currents by 81% at
10mm and lidocaine inhibits hERG by 25% at 100mm. Indeed,
in this study, 28.3% of the hERG inhibitors tested in an APD
assay did not prolong repolarization. On the other hand,
compounds that prolong QT and APD, but have no effect on
the hERG current in vitro include those that prolong
repolarization via another mechanism (see Lu et al., 2007;
Lacerda et al., 2008): (1) inhibition of IKs current (such as with
HMR 1556); (2) inhibition of Ito current (transient outward
current) (such as with 4-aminopyridine); (3) blockade of IK1
current (such as with BaCl2); (4) an increase in inward
depolarizing current (Ca
2þcurrent, such as with Bay K
8644); (5) augmentation of late INa current (sodium current)
through application of veratridine or ATX-II (Shimizu and
Antzelevitch, 1997). Based on data from the Cardiovascular
Safety Department within Johnson & Johnson, 25.7% of the
compounds that did not affect hERG-mediated current
increased the APD. In these cases, the standard hERG test
alone is not able to reliably provide a mechanism for APD and
QT prolongation in vitro or in vivo. In addition, such studies
may be limited by the physicochemical properties of the
compound (that is, poor solubility) for use in such in vitro
experiments or may be absorbed by the glass and plastic
surfaces used in the experimental apparatus, resulting in
exposure of the cells to artefactually lower concentrations.
Drug-induced short QT and possible mechanisms
Since 2000, there has been increasing evidence that short QT
syndromes constitute a new primary electrical abnormality
with high incidence of sudden death, resulting not from
TdPs, but rather from VF (Gussak et al., 2000; Gaita et al.,
2003; Schimpf et al., 2005). However, the mechanism(s)
responsible for drug-induced or acquired short QT syn-
dromes are much less known.
The short QT syndrome is characterized by familial sudden
death, short ventricular refractory periods and inducible VF,
even in young patients and newborns (Borggrefe et al., 2005;
Giustetto et al., 2006). ‘Gain-of-function’ mutations in three
different genes encoding cardiac potassium channels (speci-
fically KCNH2, KCNQ1 and KCNJ2, which are responsible for
an increase in IKr current) (Borggrefe et al., 2005) as well as
‘loss-of-function’ mutations in genes encoding the cardiac
L-type calcium channel (Antzelevitch et al., 2007) have been
associated to date with the congenital short QTsyndrome. In
all these cases, there is a resulting increase in ventricular
repolarizing current leading to a shortening of the APD,
subsequent reduction in the ventricular refractory period
and, as a consequence, a shortening of the QT interval.
Although the congenital short QT has only been recognized
recently, the existence of acquired short QT has been known
for a long time. It has been shown that acquired short QT
intervals can result from altered electrolyte levels such as
hypercalcemia, hyperkalemia and myocardial ischaemia and
may also result from elevated acetylcholine and catechola-
mine plasma levels, hyperthermia and tachycardia (Nieren-
berg and Ransil, 1979; Karjalainen and Viitasalo, 1986).
However, although such physiological mechanisms have
been examined, the mechanisms responsible for a drug-
induced short QT interval have not been adequately
elucidated or defined. In this study, we confirm at least
two mechanisms through which drugs can shorten QT and
APD and induce VT and VF, that is, activation of the ATP-
sensitive potassium current (K
þ
ATP) channel and activation of
hERG current (IKr). Drug-induced short QT both by K
þ
ATP
channel openers and IKr activators, on the other hand, can be
anti-arrhythmic under certain conditions, both in man
(Shimizu et al., 1998) and in an experimental setting (Hansen
et al., 2007).
K
þ
ATP channel openers are already known to accelerate
ventricular repolarization resulting from a shortened APD
and effective refractory period (Escande et al., 1989; Robert
et al., 1997; Milberg et al., 2007). Furthermore, the activation
of the K
þ
ATP channel is potentially pro-arrhythmic as it elicits
VTand VF in vitro in isolated hearts (Robert et al., 1997, 1999;
Milberg et al., 2007) and in vivo (de La Coussaye et al., 1993;
Wilde, 1994). Indeed, the activation of the K
þ
ATP channel
with pinacidil shortened the QT interval, increased maximal
transmural dispersion of repolarization or dispersion of the
repolarization between the left and right ventricles and
elicited VT with a programmed extra stimulus (S2) in the dog
ventricular wedge preparation and isolated rabbit heart
(Extramiana and Antzelevitch, 2004; Milberg et al., 2007).
In this study, we investigated potential arrhythmogenic
effects, in isolated rabbit hearts, of two K
þ
ATP channel openers
(levcromakalim and nicorandil; Escande et al., 1989; Robert
et al., 1997 and Milberg et al., 2007). These two compounds,
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interval and APD, and increased Tp-Te and rTp-Te (para-
meters of transmural dispersion) (Shimizu and Antzelevitch,
1997; Yan et al., 2001), instability of the action potential
(Figures 8–10) and coronary flow (the latter through their
coronary vasodilator action). The effects were most pro-
nounced with levcromakalim and were associated with an
incidence of VF of 87.5% in the isolated hearts. The low
incidence of arrhythmia with nicorandil was only observed
at a very high concentration (100mM), which is likely to be
much higher than the therapeutic plasma levels of the
compound achievable in man.
The inhibition of the hERG cardiac K
þ channel leads to
action potential prolongation on the cellular level, a
prolongation of the QT interval on the electrocardiogram
and, occasionally, cardiac arrhythmias, whereas the activa-
tion of hERG current (IKr) with mallotoxin or NS1643 was
recently shown to shorten APD (Zakharov et al., 2005; Casis
et al., 2006; Hansen et al., 2006; Zeng et al., 2006).
Furthermore, increasing IKr by overexpression of hERG
currents, either by adenoviral transfer in the rabbit or guinea
pig or by transgenic modification in mouse was reported to
shorten APD (Nuss et al., 1999; Royer et al., 2005). However,
the relationship between drug-induced shortening of APD
and QT interval by the activation of IKr current and
proarrhythmic events such as VT/VF is not well understood.
In this study, we showed that both mallotoxin and NS1643
activated hERG current by 87% and 55% at 3mM, respectively.
Mallotoxin is a relatively non-specific cardiac ion channel
activator. In addition to hERG channel activation, the toxin
(at 0.5mM) also activates Ca
2þ-activated K
þ channels in HEK
cells stably expressing the BK channel (SLO1) (Zakharov
et al., 2005). Furthermore, mallotoxin is also a protein kinase
C and calcium/calmodulin-dependent protein kinase II
inhibitor, with IC50 values of 3–6mM (Ginnan et al., 2004).
NS1643, on the other hand, has been shown to be a more
specific hERG activator, with an EC50 of 15mM (Casis et al.,
2006), although our current study showed a 55% increase at
3mM.
In this study, in isolated Langendorff-perfused hearts, both
mallotoxin and NS1643 shortened APD and the QT interval.
These two compounds also consistently increased Tp-Te,
rTp-Te and coronary flow (by a presently unknown mechan-
ism). Furthermore, the shortening of APD and QT interval by
these two compounds was associated with a pro-arrhythmic
potential, demonstrated by the very high incidence of VF (in
all seven hearts at a concentration of 1mM with mallotoxin,
and in four out of the six hearts with NS1643 at 10mM) in the
isolated rabbit heart model. In contrast to reliable increases
in Tp-Te and some degree of QT and APD shortening, the
incidence of VF did not consistently correlate with beat-to-
beat instability of the action potential. Indeed, although the
incidence of VF (a measure of proarrhythmic potential) after
NS1643 is similar to that of mallotoxin and levcromakalim,
beat-to-beat instability only marginally increased before VF in
the presence of NS1643, whereas this parameter was markedly
increased after mallotoxin and levcromakalim. The reason for
this difference has not been addressed in this study.
Physiological shortening of the QT interval, such as that
caused by increasing the heart rate, is of course not normally
proarrhythmic. In addition, increases in body temperature
markedly shorten the QT interval, without causing arrhyth-
mia in healthy dogs (Van der Linde, personal communica-
tion). However, the recently identified congenital short QT
syndromes clearly show the risks of QT shortening, and our
experimental demonstration of the potential proarrhythmic
risks of various QT-shortening drugs suggests that inap-
propriate drug-induced QT shortening can have dangers. As
discussed above, although biomarkers such as beat-to-beat
instability do not reliably predict the incidence of VF under
these conditions, Tp-Te and rTp-Te are consistently increased
in the setting of VF. Further work is required to identify both
the degree of QT shortening and coincidental biomarkers
that could be used to identify the risk of proarrhythmia in
developmental compounds.
Limitations
The compounds tested in the hERG and APD assays in this
study represent a selection of (mainly) bioactive compounds
derived from Johnson & Johnson’s current research projects,
and, although they are chemically heterogeneous, they may
not be representative of compounds tested by other
pharmaceutical companies. Nevertheless, it is increasingly
recognized that a large percentage of biologically active
compounds will inhibit the hERG current and may affect
other ion channels (Kang et al., 2004; Martin et al., 2004;
Christ et al., 2008). We therefore believe that the results
obtained in this study, where 58% of compounds tested
showed significant hERG inhibition, are representative of
present-day medicinal chemistry.
Although drug-induced VT and VF with short QT were
related to a shortening in QT or APD, exactly which
biomarkers are predictive of drug-induced short QT remains
unknown. In contrast to acquired long QT (for example,
Hondeghem et al., 2003; Lawrence et al., 2006), our data in
isolated hearts suggest that beat-to-beat instability did not
appear to play a major role in drug-induced VF in acquired
short QT. The common reason for susceptibility to
malignant ventricular tachyarrhythmias in short QT is likely
the large dispersion of ventricular refractoriness caused by
the inhomogeneous abbreviation of the action potential
within the ventricle and within different layers of the
ventricular wall (Gaita et al., 2003; Borggrefe et al., 2005).
However, although it is difficult to measure the dispersion in
different layers of the ventricle, we were able to show that
mallotoxin and the two K
þ
ATP channel openers tested
significantly increased ventricular transmural dispersion
taken from the transmural ECG (Tp-Te and rTp-Te). Indeed,
these increases in dispersion were secondary to the signifi-
cant shortening in QT/APD. Additional studies are needed to
determine which additional parameters may play an
important role in drug-induced short QT and VT/VF. One
of the possibility may be the wavelength, l, defined as
conduction velocity effective refractory period
((ERP)¼ERP/CT) and it may have a key role in predicting
drug-induced VT/VF associated with short QT (see Honde-
ghem, 2006). When l decreases by shortening QT and APD
or slowing the conduction velocity, reentry arrhythmias
such as VT and VF are most likely to occur (Girouard and
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crucial role in drug-induced short QT because we did not
measure effective refractory period. Further studies are
needed to determine the importance of l in drug-induced
short QT.
Conclusions
Although the current ICHS7B regulatory guidelines (ICH
S7B, 2005) may be useful for predicting drug-induced QT
prolongation, amendments to these guidelines may be
warranted in the future to address the potential liability for
drug-induced short QT and the associated fatal arrhythmias.
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